Gabriela Hobbs: Emerging Myelofibrosis Therapies at EHA 2026
Gabriela Hobbs, Leukemia Clinical Director at Massachusetts General Hospital, Associate Professor at Harvard Medical School, shared Priya Sriskandarajah’s post on LinkedIn:
“Thankful for the opportunity to discuss emerging therapies in Myelofibrosis at this year’s EHA in lovely Sweden with Stefan Schleding, Gonzalo Carreño and Steffen Koschmieder.”
Priya Sriskandarajah, Consultant Haematologist at Guy’s and St Thomas’ NHS Foundation Trust, shared a post on LinkedIn:
“Next session covering management of cytopenic myelofibrosis – a very challenging cohort but some exciting new therapies coming especially combination options.
Excellent presentations by Stefan Scheding, Gonzalo Carreno and Gabriela Hobbs with chair Steffen Koschmieder.”
Stay updated with Hemostasis Today.
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?
-
Nov 8, 2026, 17:36Paschalis Evangelidis: The Multifactorial Nature of Cardiovascular Risk in People With Hemophilia
-
Nov 8, 2026, 17:32Evangelos Panagiotopoulos: Apixaban Reduces Stroke and Major Bleeding Risk in Secondary Stroke Prevention
-
Nov 8, 2026, 17:27Danny Gaskin: Applications Open for the BBTS Specialist Certificate in Clinical Transfusion Practice
-
Nov 8, 2026, 16:54James P. Crowley: DOAC Testing Under 50 ng/mL Safely Expedites Urgent Hip Fracture Surgery
-
Nov 8, 2026, 16:21Alessandra Bosch: Women and Girls With Bleeding Disorders and the DACH Registries at HHS 2026
-
Nov 8, 2026, 15:0310 Posts Not to Miss This Week
-
Nov 8, 2026, 14:55Andra T.: Antiphospholipid Syndrome and Its Thrombotic Risks